DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Renin-Angiotensin System in Essential Hypertension

Information source: St George's, University of London
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Enalapril 20 mg bd (Drug); Candesartan 8 mg bd (Drug)

Phase: N/A

Status: Terminated

Sponsored by: St George's, University of London

Official(s) and/or principal investigator(s):
Timothy WR Doulton, BSc MRCP, Principal Investigator, Affiliation: SGUL

Summary

Although ACE Inhibitors and Angiotensin Receptor Blockers are effective blood pressure lowering agents, the exact mechanisms by which these agents lower BP are still not fully understood. This study aims to compare the blood pressure and hormonal responses (plasma renin activity and aldosterone) to the ACE inhibitor enalapril and ARB candesartan in individuals with mild essential hypertension.

Clinical Details

Official title: The Renin-Angiotensin System in Essential Hypertension

Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome:

Change in BP

Change in PRA and aldosterone

Eligibility

Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Essential Hypertension

- SBP 140-159 mmHg

- DBP 90-99 mmHg

Exclusion Criteria:

- Intolerance of or allergy to ACE Inhibitors or ARBS

- Pregnant or Breastfeeding

- Pre-menopausal women

- Uncontrolled cardiac or renal failure

- Diabetes mellitus

Locations and Contacts

Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL, London SW17 0RE, United Kingdom
Additional Information

Starting date: April 2004
Last updated: June 5, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017